MAO-B-IN-33
MAO-B-IN-33 (compound C3) is a potent, reversible and selective monoamine oxidase-B (MAO-B) inhibitor with an IC50 of 0.021 μM and 26.805 μM for MAO-B and MAO-A, respectively. The selectivity of MAO-B-IN-33 is attributed to the steric clash arising from the residue differences between Phe208 (MAO-A) and Ile199 (MAO-B). MAO-B-IN-33 inhibits cerebral MAO-B activity and alleviates MPTP (HY-15608)-induced dopaminergic neuronal loss in the mouse. MAO-B-IN-33 has the potential for Parkinson's disease research.
For research use only. We do not sell to patients.
- CAS No.: 2286257-25-6
- Formula: C18H19FN2O2
- Molecular Weight:314.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-113468
3-O-Methyl-DL-DOPAEndogenous Metabolite -
HY-113468R
3-O-Methyl-DL-DOPA (Standard)Endogenous Metabolite -
HY-145512
N-(α-Linolenoyl) tyrosineDopaminergic Agonist -
HY-125339
Ro 41-0960COMT Inhibitor -
HY-14199
Selegiline hydrochlorideMAO-B Inhibitor -
HY-120419
PF9601NMAO-B Inhibitor -
HY-139089
(Z)-Entacapone
Biological Activity
Description
IC50 & Target
[1]|
MAO-B 0.021 μM (IC50) |
MAO-A 26.805 μM (IC50) |
Chemical Information
-
CAS No. 2286257-25-6
-
Molecular Weight 314.35
-
Formula C18H19FN2O2
-
SMILES
NC([C@@H]1CCN1CC2=CC=C(OCC3=CC(F)=CC=C3)C=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MAO-B-IN-33 Related Classifications
HY-158732 Related Classifications
Powered by Bioz